Deutsche Bank Ag\ Satsuma Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 04, 2021	SELL	$4.54 - $7.17 $94,613 - $149,422	-20,840 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$4.8 - $7.25 $68,548 - $103,537	14,281 Added 217.73%	20,840 $147,000
Q1 2021 May 13, 2021	SELL	$4.57 - $7.18 $25,966 - $40,796	-5,682 Reduced 46.42%	6,559 $38,000
Q4 2020 Feb 16, 2021	BUY	$3.56 - $5.09 $6,511 - $9,309	1,829 Added 17.57%	12,241 $57,000
Q3 2020 Nov 12, 2020	BUY	$3.85 - $28.47 $21,459 - $158,691	5,574 Added 115.21%	10,412 $40,000
Q2 2020 Aug 13, 2020	BUY	$16.01 - $34.69 $50,607 - $109,655	3,161 Added 188.49%	4,838 $139,000
Q1 2020 May 14, 2020	BUY	$14.53 - $30.69 $2,833 - $5,984	195 Added 13.16%	1,677 $36,000
Q4 2019 Feb 14, 2020	BUY	$9.32 - $19.68 $13,812 - $29,165	1,482 New	1,482 $29,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.